nanoTox Inc., the first
company to provide complete risk assessment - and solutions - exclusively
for nanoparticles, announced today that its Chief Scientific Officer, Dr. David
W. Hobson, will share his insight on impending regulations and policies surrounding
nanotech product safety during the NSTI Nanotech conference and exposition in
Houston, Texas. The panel, entitled "Nanotech Policy, Regulation and Product
Safety," will take place at 1:30 pm on May 5, 2009 at the George R. Brown
Dr. Hobson is a toxicological expert on safety issues related to the commercialization
of nanotechnology and is a noted consultant to government and industry on nanoproduct
and nanotechnology development issues.
"The nanotechnology platform is demonstrating amazing potential for the
development of advanced technologies and products in many business sectors,"
stated Dr. Hobson. "Recent actions in the U.S. and abroad requiring nanotechnology
companies to list certain materials they incorporate into commercial products
are just the start of events that will have lasting effects on nanotechnology
companies and the marketplace for nanoproducts."
Dr. Hobson has 30 years of practical experience in toxicological research and
development, including environmental, industrial, and medical projects for government,
industry and private concerns. His experience with nanomaterials includes pharmacological
and toxicological research using in vitro and in vivo pre-clinical models; preparation
of medical device submissions to regulatory agencies, as well as chemistry and
manufacturing controls and pharmacology/toxicology sections for new drug applications.
His work with nanoTox includes establishing state-of-the-art facilities and
test procedures, which are employed for clients under strict confidentiality
and in accordance with established U.S. good laboratory practices and international
data quality standards.
Dr. Hobson is a past president of the American College of Toxicology and an
editorial advisor to the International Journal of Toxicology. He teaches courses
in biophysics, nuclear pharmacy, immunoassay and radiation biology at the University
of the Incarnate Word in San Antonio.
Dr. Hobson has many scientific publications to his credit including the book
Dermal and Ocular Toxicology: Fundamentals and Methods; and book chapters on
product risk assessment, toxicology study design, toxicology of wound healing,
dermal toxicology and gastrointestinal toxicology. He has led successful projects
including all aspects of pharmaceutical development - from discovery,
development and registration to post-market support - which have resulted
in currently marketed pharmaceutical products and numerous patents.
nanoTox will be exhibiting at the NSTI Nanotech conference and exposition May
3-7, 2009. The nanoTox booth, #907, will be located near the front of the exhibit